© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Latest Conference Articles
AI Diagnostics Fall Short in Skin of Color
April 27th 2021
Artificial intelligence diagnostics are less accurate on skin of color than light skin, even when trained on equal numbers of images.
Tips to Improve High-Risk Skin Cancer Management
April 26th 2021
American Academy of Dermatology
In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.
Voltaire-X Phase 3 Data for Chronic Plaque Psoriasis Support Interchangeability Application
April 26th 2021
American Academy of Dermatology
Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.
‘Zoom Dysmorphia’ Becoming Rising Issue Among Patients
April 26th 2021
American Academy of Dermatology
A survey found a large proportion of dermatologists surveyed said their patients referenced video conferencing as the reason for seeking cosmetic consultation since the start of the pandemic.
Bimekizumab Beats Secukinumab in Skin Clearance for Psoriasis
April 26th 2021
American Academy of Dermatology
In phase 3b data presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021 showed bimekizumab achieved superior levels of complete skin clearance compared to secukinumab for psoriasis.
Otezla Phase 3 ADVANCE Trial Reports Improvement in Plaque Psoriasis Severity
April 25th 2021
American Academy of Dermatology
Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.
Phase 2 Study of Ruxolitinib Cream for Vitiligo Announces New Findings
April 25th 2021
American Academy of Dermatology
Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.
Game Changers in Dermatology
April 25th 2021
American Academy of Dermatology
Experts in core dermatological specialties share their insights on the game-changing research and innovation that advancing skin disease management and patient care.
Tremfya Phase 3 Data Show Continued Clearance After 5 Years
April 25th 2021
American Academy of Dermatology
Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.
New Officers, Board Members Elected to AAD
April 25th 2021
American Academy of Dermatology
The American Academy of Dermatology Announced the results from its annual election, with 2 officers and 4 board members assuming their new positions in March 2022.